Drug Type Small molecule drug |
Synonyms Isuzinaxib Hydrochloride + [1] |
Target |
Action inhibitors |
Mechanism NOX inhibitors(NADPH oxidase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC17H17N3O |
InChIKeyLQKQLKMTJOMCMJ-UHFFFAOYSA-N |
CAS Registry1270084-92-8 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus, Type 2 | Phase 3 | Hungary | 24 Aug 2020 | |
Diabetes Mellitus, Type 2 | Phase 3 | Serbia | 24 Aug 2020 | |
Diabetes Mellitus, Type 2 | Phase 3 | Czechia | 24 Aug 2020 | |
Diabetes Mellitus, Type 2 | Phase 3 | Bulgaria | 24 Aug 2020 | |
Acute Kidney Injury | Phase 2 | United States | 27 Dec 2023 | |
Acute Kidney Injury | Phase 2 | South Korea | 27 Dec 2023 | |
COVID-19 | Phase 2 | United States | 20 Oct 2021 | |
Diabetic Nephropathies | Phase 2 | - | - |
NCT04534439 (ASN2022) Manual | Phase 2 | 140 | (oowctretxy) = lofigaxoor npwblnvjeo (vcjzzseong ) View more | Positive | 04 Nov 2022 | ||
Placebo | (oowctretxy) = qfcxsnfkdt npwblnvjeo (vcjzzseong ) View more |